by Clinical Neuropsychologist | Wednesday, January 8, 2025 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Timothy Daly, Kasper P. Kepp, Bruno P. Imbimbo | January 8,...
by Clinical Neuropsychologist | Wednesday, January 8, 2025 | Dementia
Abstract INTRODUCTION The importance of protein amyloidogenesis, associated with various diseases and functional roles, has driven the creation of computational predictors of amyloidogenicity. The accuracy of these predictors, particularly those utilizing artificial...
by Clinical Neuropsychologist | Wednesday, January 8, 2025 | Dementia
Abstract INTRODUCTION Sarcopenia, with its complex diagnostic process, is a likely independent predictor of poor prognosis in patients with Alzheimer’s disease (AD). However, research on the clinical characteristics and biomarkers of AD patients with sarcopenia...
by Clinical Neuropsychologist | Wednesday, January 8, 2025 | Dementia
Abstract INTRODUCTION Amyloid beta (Aβ) plaques and hyperphosphorylated tau in the entorhinal regions are key Alzheimer’s disease (AD) markers, but the spatial Aβ pathways influencing tau pathology remain unclear. METHODS We applied predictive modeling to...
by Clinical Neuropsychologist | Wednesday, January 8, 2025 | Dementia
Abstract INTRODUCTION Plasma-based biomarkers have shown promise for clinical implementation, but their accuracy in differentiating Alzheimer’s disease (AD) from syndromes associated with frontotemporal lobar degeneration (FTLD) has yet to be fully investigated....
by Clinical Neuropsychologist | Wednesday, January 8, 2025 | Dementia
Abstract INTRODUCTION Plaques are a hallmark feature of Alzheimer’s disease (AD). We found that the loss of mucosal-associated invariant T (MAIT) cells and their antigen-presenting molecule MR1 caused a delay in plaque pathology development in AD mouse models....
